HCQ

"Rep. Biggs: Big Pharma Won't Consider Therapeutics Like HCQ or Ivermectin Because of Economic Interests," the offending tweet read, with an attached link to video of Bigg's comments.

He then lists some of these "treatments" as "monoclonal antibodies, ivermectin, zinc, vitamin C and D, and HCQ."

The FDA has for years approved HCQ to treat malaria, Lupus and rheumatoid arthritis.

Dr. Risch, a professor of epidemiology at Yale School of Medicine, is a public advocate for administering HCQ to outpatients.

Dr. Risch and three other medical doctors gathered their data from five existing randomized HCQ drug trials in the U.S.,